ASH 2023 | Dose reductions to manage AEs of ibrutinib treatment for CLL
Mazyar Shadman, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, discusses the benefit of reducing doses of ibrutinib to manage adverse events (AEs) in the treatment of chronic lymphocytic leukemia (CLL). An analysis of the ConcertAI database revealed that the time-to-next treatment or death (TNT-D) was significantly improved by reducing doses following AEs. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Eli Lilly, BeiGene, Fate Therapeutics, Janssen, Kite, a Gilead Company, Bristol Myers Squibb, MorphoSys/Incyte, AstraZeneca, Pharmacyclics, Mustang Bio, Genmab, ADC therapeutics, Genentech, AbbVie, MEI Pharma, Regeneron; Research Funding: BeiGene, Bristol Myers Squibb, MorphoSys/Incyte, AstraZeneca, Pharmacyclics, Mustang Bio, Genmab, Vincerx, Genentech, AbbVie, TG Therapeutics.
